Arsenic trioxide enhances the chemotherapeutic efficiency of cisplatin in cholangiocarcinoma cells via inhibiting the 14-3-3ε-mediated survival mechanism
- Elijah
- 0
Cholangiocarcinoma (CCA) is the second most frequent main liver carcinoma with excessive levels of malignancy and mortality. Chemotherapy performs a key position within the remedy of CCA, nonetheless, the low chemotherapeutic effectivity results in a bottleneck.
So unraveling the potential mechanisms to reinforce the effectivity (lowered the dosage and enhanced the consequences of chemotherapy medicine) and figuring out different therapeutic methods in CCA are urgently wanted.
Right here, we discovered that, in CCA cells, when cisplatin (CDDP) displayed anti-tumor results, it activated 14-3-3ε concurrently, which in flip fashioned a survival mechanism through the phosphorylation of phosphatidylinositol 3-kinase/protein kinase B (PI-3K/Akt). Nonetheless, low concentrations of arsenic trioxide (ATO) might disrupt such survival mechanism and enhanced the effectivity.
For the molecular mechanisms, ATO attenuated 14-3-3ε at each transcriptional and post-transcriptional (ubiquitination degradation) ranges. Such repressive impact blocked the activation of PI-3K/Akt, and its downstream anti-apoptotic elements, B-cell lymphoma 2 (Bcl-2), and survivin. Collectively, our current research revealed that the synergistic results of ATO and CDDP could possibly be a novel strategy for enhancing the effectivity, which supplies an revolutionary therapeutic imaginative and prescient for the remedy of CCA.
Lengthy-Time period High quality of Lifetime of Acute Promyelocytic Leukemia Sufferers Handled with Arsenic Trioxide versus Chemotherapy
The principle goal of this research was to check the long-term health-related high quality of lifetime of sufferers with acute promyelocytic leukemia (APL) handled with all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) versus ATRA plus customary chemotherapy.
Sufferers beforehand enrolled within the randomized managed trial APL0406 have been thought-about eligible for this follow-up research. The next patient-reported end result measures have been used: the EORTC QLQ-C30, the EORTC QLQ-CIPN20 and the SF-36. The prevalence of late comorbidities and well being issues was additionally assessed.
The scientific significance of variations was evaluated primarily based on predefined thresholds. This research was registered. 100 sixty-one out of 232 doubtlessly eligible sufferers have been analyzed, of whom 83 have been handled with ATRA-ATO and 78 have been handled with ATRA-chemotherapy. The median time since prognosis of the research pattern was Eight years.
The 2 largest clinically significant variations within the EORTC QLQ-C30 have been noticed for position functioning (Δ=8.4, 95% CI, 0.5 to 16.3) and dyspnea (Δ=-8.5, 95% CI, -16.Four to -0.7), favoring sufferers handled with ATRA-ATO.
With regard to the SF-36 outcomes, a clinically related higher bodily element rating (Δ=4.6, 95% CI, 1.Three to 7.8) was noticed in sufferers handled with ATRA-ATO, however this was not the case for the psychological element rating. The 2 teams confirmed comparable profiles within the scores of the EORTC QLQ-CIPN20 scales and within the prevalence of late comorbidities.
General, our findings counsel that the larger and extra sustained antileukemic efficacy of ATRA-ATO can also be related to higher long-term patient-reported outcomes than ATRA-chemotherapy.
New Bioactive Calcium Silicate Cement Mineral Trioxide Combination Restore Excessive Plasticity (MTA HP)-A Systematic Assessment
Bioactive calcium silicate cement Mineral Trioxide Combination (MTA) has been used for years as a gold customary in intravital pulp remedy and specialist endodontic procedures.
Owing to flaws of the fabric, the producers have been making an attempt to reinforce and produce supplies displaying improved bodily, chemical and organic parameters. One of many new calcium-silicate cements primarily based on mineral trioxide mixture, nonetheless with out some flaws exhibited by the cement, is Mineral Trioxide Combination Restore Excessive Plasticity (MTA HP).
The intention of the current paper was a scientific literature assessment regarding the MTA HP materials used these days in dentistry, as a assessment of its particular options. The current paper is the primary article offering a scientific literature assessment on MTA HP.
The intention of the current article is the higher understanding of MTA HP properties, which may support the decision-making course of in endodontic remedy.
Genetic Expression Screening of Arsenic Trioxide-Induced Cytotoxicity in KG-1a Cells Based mostly on Bioinformatics Expertise
Acute myeloid leukemia (AML) is a malignant tumor of the hematopoietic system, and leukemia stem cells are chargeable for AML chemoresistance and relapse. KG-1a cell is taken into account a leukemia stem cell-enriched cell line, which is immune to chemotherapy.
Arsenic trioxide (ATO) is efficient in opposition to acute promyelocytic leukemia as a first-line remedy agent, at the same time as remission induction of relapsed instances. ATO has a cytotoxic impact on KG-1a cells, however the mechanism stays unclear. Our outcomes demonstrated that ATO can inhibit cell proliferation, induce apoptosis, and arrest KG-1a cells within the G2/M part.
Utilizing transcriptome evaluation, we investigated the candidate goal genes regulated by ATO in KG-1a cells. The expression profile evaluation confirmed that the ATO had considerably modified gene expression associated to proliferation, apoptosis, and cell cycle. Furthermore, MYC, PCNA, and MCM7 have been recognized as essential hub genes by means of protein-protein interplay community evaluation; in the meantime, the expressions of them in each RNA and protein ranges are down-regulated as confirmed by quantitative polymerase chain response and Western blot.
Thus, our research means that ATO not solely inhibits the expression of MYC, PCNA, and MCM7 but additionally results in cell cycle arrest and apoptosis in KG-1a cells. General, this research offered dependable clues for bettering the ATO efficacy in AML
Ultrasonically assisted conversion of uranium trioxide into uranium(VI) intrinsic colloids
Beneath oxidizing situations, the corrosion of spent nuclear gasoline might result in the leaching of radionuclides together with soluble uranyl-based species. The speciation of the generated chemical varieties is complicated and the associated potential formation of colloidal species seems surprisingly poorly reported within the literature.
Their formation might nonetheless contribute considerably to the mobility of radionuclides within the surroundings. A greater data within the speciation and reactivity of those species seems notably related. This research describes the preparation and characterization of intrinsic uranium(vi) colloids from amorphous and crystalline UO3 in pure water assisted by 20 kHz ultrasound.
Within the presence of carbon monoxide stopping the sonochemical formation of hydrogen peroxide, ultrasonic remedy boosts the conversion of UO3 powder into (meta-)schoepite precipitates and yields very secure and notably concentrated uranium(vi) nanoparticles within the liquid part. Utilizing HR-TEM, SAXS and XAS strategies, we confirmed that the colloidal suspension consists of quasi-spherical nanoparticles measuring ca. 3.8 ± 0.Three nm and exhibiting a schoepite-like crystallographic construction.
Chromium trioxide |
|||
GRM1057-1KG | EWC Diagnostics | 1 unit | EUR 21.58 |
Description: Chromium trioxide |
Chromium trioxide |
|||
GRM1057-500G | EWC Diagnostics | 1 unit | EUR 12.03 |
Description: Chromium trioxide |
Vanadium trioxide |
|||
V00590 | Pfaltz & Bauer | 25G | EUR 217.95 |
MOLYBDENUM TRIOXIDE |
|||
M488 | PhytoTechnology Laboratories | 100G | EUR 221.93 |
Molybdenum Trioxide |
|||
M489008 | Toronto Research Chemicals | 2.5g | EUR 69 |
Description: 1313-27-5 |
Molybdenum trioxide |
|||
PCT0114-100G | EWC Diagnostics | 1 unit | EUR 36.19 |
Description: Molybdenum trioxide |
Molybdenum trioxide |
|||
PCT0114-500G | EWC Diagnostics | 1 unit | EUR 162.62 |
Description: Molybdenum trioxide |
Molybdenum trioxide |
|||
GRM1796-100G | EWC Diagnostics | 1 unit | EUR 30.91 |
Description: Molybdenum trioxide |
Molybdenum trioxide |
|||
GRM1796-500G | EWC Diagnostics | 1 unit | EUR 138.79 |
Description: Molybdenum trioxide |
di-Boron Trioxide |
|||
05219-65 | NACALAI TESQUE | 500G | EUR 16.8 |
di-Boron Trioxide |
|||
05220-12 | NACALAI TESQUE | 25G | EUR 10.15 |
di-Boron Trioxide |
|||
05220-25 | NACALAI TESQUE | 500G | EUR 34.3 |
Bismuth trioxide 99% |
|||
B15890 | Pfaltz & Bauer | 100G | EUR 254 |
Rhenium trioxide 99.9% |
|||
R01120 | Pfaltz & Bauer | 1G | EUR 441.89 |
di-Boron trioxide |
|||
RM6690-250G | EWC Diagnostics | 1 unit | EUR 51.89 |
Description: di-Boron trioxide |
Chromium trioxide 99% |
|||
C21915 | Pfaltz & Bauer | 25G | EUR 129.65 |
Tungsten trioxide 99.8% |
|||
T33330 | Pfaltz & Bauer | 100G | EUR 326.6 |
Trimethylamine sulfur trioxide |
|||
T26520 | Pfaltz & Bauer | 5G | EUR 118.66 |
Molybdenum trioxide 99.5%_x000D__x000D_ |
|||
M31150 | Pfaltz & Bauer | 100G | EUR 227.4 |
SULFUR TRIOXIDE PYRIDINE COMPLEX |
|||
719008 | Survival Technologies | each | Ask for price |
Pyridine/sulfur trioxide complex |
|||
P30210 | Pfaltz & Bauer | 25G | EUR 186.1 |
Pyridine-Sulfur Trioxide Complex |
|||
P991560 | Toronto Research Chemicals | 10g | EUR 64 |
Description: 26412-87-3 |
Sulfur Trioxide Triethylamine Complex |
|||
S789455 | Toronto Research Chemicals | 10g | EUR 64 |
Description: 761-01-3 |
Sulfur Trioxide Trimethylamine Complex |
|||
S789465 | Toronto Research Chemicals | 10g | EUR 236 |
Description: 3162-58-1 |
Arsenic Trioxide Standard 100ppm - 1L |
|||
AR2O3-CO | Scientific Laboratory Supplies | 1L | EUR 299.7 |
USP Stock Sol. to make Arsenic Trioxide - 100ML |
|||
USP6701 | Scientific Laboratory Supplies | 100ML | EUR 140.4 |
USP Stock Sol. to make Arsenic Trioxide - 500ML |
|||
USP6705 | Scientific Laboratory Supplies | 500ML | EUR 581.85 |
SULFUR TRIOXIDE DIMETHYL FORMAMIDE COMPLEX |
|||
919007 | Survival Technologies | each | Ask for price |
Sulfur trioxide N,N-dimethylformamide Complex |
|||
S789460 | Toronto Research Chemicals | 10g | EUR 64 |
SULFUR TRIOXIDE TRIETHYLAMINE COMPLEX (TEA.SO3 COMPLEX) |
|||
919008 | Survival Technologies | each | Ask for price |
Antimony trichloride, Hi-AR™/ACS |
|||
GRM1632-250G | EWC Diagnostics | 1 unit | EUR 42.3 |
Description: Antimony trichloride, Hi-AR™/ACS |
Antimony trichloride, Hi-AR™/ACS |
|||
GRM1632-500G | EWC Diagnostics | 1 unit | EUR 76.1 |
Description: Antimony trichloride, Hi-AR™/ACS |
Antimony trifluoride |
|||
A34670 | Pfaltz & Bauer | 5G | EUR 92.6 |
Antimony trichloride |
|||
GRM1274-250G | EWC Diagnostics | 1 unit | EUR 38.42 |
Description: Antimony trichloride |
Antimony trichloride |
|||
GRM1274-500G | EWC Diagnostics | 1 unit | EUR 69.19 |
Description: Antimony trichloride |
Antimony triphenyl_x000D__x000D_ |
|||
A34730 | Pfaltz & Bauer | 25G | EUR 177.48 |
Antimony triethyl 97% |
|||
A34660 | Pfaltz & Bauer | 10G | EUR 17877.8 |
Antimony triiodide 99% |
|||
A34680 | Pfaltz & Bauer | 100G | EUR 383.88 |
Antimony tribromide 98% |
|||
A34620 | Pfaltz & Bauer | 10G | EUR 193.97 |
Antimony trichloride 99% |
|||
A34650 | Pfaltz & Bauer | 50G | EUR 221.15 |
Antimony trisulphide, Hi-LR™ |
|||
GRM3039-500G | EWC Diagnostics | 1 unit | EUR 68.41 |
Description: Antimony trisulphide, Hi-LR™ |
Antimony oxalate |
|||
A34470 | Pfaltz & Bauer | 10G | EUR 370.13 |
Antimony acetate |
|||
20-abx181235 | Abbexa |
|
|
Antimony phosphate |
|||
A34530 | Pfaltz & Bauer | 1G | EUR 252.01 |
Antimony Tetroxide |
|||
A34610 | Pfaltz & Bauer | 10G | EUR 154.31 |
Antimony pentoxide |
|||
GRM1945-250G | EWC Diagnostics | 1 unit | EUR 51.66 |
Description: Antimony pentoxide |
Antimony oxychloride |
|||
A34480 | Pfaltz & Bauer | 1G | EUR 155.96 |
Antimony oxychloride |
|||
GRM1943-500G | EWC Diagnostics | 1 unit | EUR 77.79 |
Description: Antimony oxychloride |
Antimony(Ⅲ) Oxide |
|||
03223-42 | NACALAI TESQUE | 25G | EUR 18.2 |
Antimony(Ⅲ) Oxide |
|||
03223-71 | NACALAI TESQUE | 1G | EUR 11.2 |
Antimony Ingot, 99.9999% |
|||
GX7081-250 | Glentham Life Sciences | 250 | EUR 648.5 |
Antimony Ingot, 99.9999% |
|||
GX7081-50 | Glentham Life Sciences | 50 | EUR 249.2 |
Antimony Ingot, 99.999% |
|||
GX8708-100 | Glentham Life Sciences | 100 | EUR 277.1 |
Antimony Ingot, 99.999% |
|||
GX8708-500 | Glentham Life Sciences | 500 | EUR 728.4 |
Antimony(III) Oxide |
|||
A697530 | Toronto Research Chemicals | 25g | EUR 58 |
Description: 1309-64-4 |
Antimony Pieces, 99.999% |
|||
GX7845-100 | Glentham Life Sciences | 100 | EUR 340.5 |
Antimony Pieces, 99.999% |
|||
GX7845-25 | Glentham Life Sciences | 25 | EUR 134.1 |
Antimony Pieces, 99.999% |
|||
GX7845-500 | Glentham Life Sciences | 500 | EUR 1218.8 |
Antimony Pieces, 99.9999% |
|||
GX8733-25 | Glentham Life Sciences | 25 | EUR 180.9 |
Antimony Pieces, 99.9999% |
|||
GX8733-250 | Glentham Life Sciences | 250 | EUR 751 |
Antimony Pieces, 99.9999% |
|||
GX8733-50 | Glentham Life Sciences | 50 | EUR 283.5 |
Antimony sulfide 98% |
|||
A34575 | Pfaltz & Bauer | 100G | EUR 205.8 |
Antimony(Ⅲ) Chloride |
|||
03215-52 | NACALAI TESQUE | 25G | EUR 14 |
Antimony(Ⅲ) Chloride |
|||
03215-65 | NACALAI TESQUE | 500G | EUR 57.4 |
Antimony Arsenide 99.999% |
|||
A34427 | Pfaltz & Bauer | 1G | EUR 146.56 |
Antimony(V) chloride |
|||
GX8478-250 | Glentham Life Sciences | 250 | EUR 200.6 |
Antimony(III) sulfide |
|||
GX5942-500 | Glentham Life Sciences | 500 | EUR 164.8 |
Antimony Phosphide 99.5% |
|||
A34531 | Pfaltz & Bauer | 5G | EUR 379.94 |
Antimony D-tartrate |
|||
A34580 | Pfaltz & Bauer | 1G | EUR 140.76 |
Antimony telluride 99% |
|||
A34590 | Pfaltz & Bauer | 1G | EUR 194 |
Antimony metal powder |
|||
GRM6598-250G | EWC Diagnostics | 1 unit | EUR 57.13 |
Description: Antimony metal powder |
Antimony (III) sulphate |
|||
GRM1946-500G | EWC Diagnostics | 1 unit | EUR 22.86 |
Description: Antimony (III) sulphate |
Antimony metal pieces |
|||
GRM3123-10G | EWC Diagnostics | 1 unit | EUR 92.81 |
Description: Antimony metal pieces |
Antimony potassium tartrate trihydrate |
|||
A100-2x25G | TOKU-E | 2 x 25 g | EUR 28.66 |
Description: K2Sb2(C4H2O6)2• 3 H2O |
Antimony potassium tartrate trihydrate |
|||
A100-4x25G | TOKU-E | 4 x 25 g | EUR 47.2 |
Description: K2Sb2(C4H2O6)2• 3 H2O |
Antimony potassium tartrate trihydrate, |
|||
GRM1779-100G | EWC Diagnostics | 1 unit | EUR 6.93 |
Description: Antimony potassium tartrate trihydrate, |
Antimony potassium tartrate trihydrate, |
|||
GRM1779-500G | EWC Diagnostics | 1 unit | EUR 28.6 |
Description: Antimony potassium tartrate trihydrate, |
Antimony sulphide black |
|||
GRM6599-500G | EWC Diagnostics | 1 unit | EUR 45.16 |
Description: Antimony sulphide black |
Antimony sodium tartrate |
|||
466052 | MedKoo Biosciences | 5.0mg | EUR 350 |
Antimony pentasulfide 97% |
|||
A34510 | Pfaltz & Bauer | 50G | EUR 147.9 |
Antimony sodium tartrate |
|||
A34560 | Pfaltz & Bauer | 25G | EUR 89 |
Antimony(V) pentasulfide |
|||
GX8145-50 | Glentham Life Sciences | 50 | EUR 145.1 |
Antimony(V) pentasulfide |
|||
GX8145-50G | Glentham Life Sciences | 50 g | EUR 211.2 |
Antimony pentachloride 99% |
|||
A34485 | Pfaltz & Bauer | 50G | EUR 334.25 |
Antimony pentafluoride 98% |
|||
A34496 | Pfaltz & Bauer | 5G | EUR 370.66 |
Antimony pentafluoride 99% |
|||
A34497 | Pfaltz & Bauer | 5G | EUR 372.96 |
Antimony(III) oxide, 98+% |
|||
GX8352-500 | Glentham Life Sciences | 500 | EUR 128.1 |
Antimony(III) oxide, 99.99+% |
|||
GX8841-100 | Glentham Life Sciences | 100 | EUR 358.4 |
Antimony(III) oxide, 99.99+% |
|||
GX8841-25 | Glentham Life Sciences | 25 | EUR 169.5 |
Antimony(III) oxide, 99.9% |
|||
GX1943-250 | Glentham Life Sciences | 250 | EUR 685.9 |
Antimony(III) oxide, 99.9% |
|||
GX1943-50 | Glentham Life Sciences | 50 | EUR 228.1 |
Antimony tin oxide, 99.95 % |
|||
GX2870-1 | Glentham Life Sciences | 1 | EUR 1079.3 |
Antimony tin oxide, 99.95 % |
|||
GX2870-100 | Glentham Life Sciences | 100 | EUR 221.7 |
Antimony tin oxide, 99.95 % |
|||
GX2870-25 | Glentham Life Sciences | 25 | EUR 129.6 |
Antimony tin oxide, 99.95 % |
|||
GX2870-250 | Glentham Life Sciences | 250 | EUR 416.4 |
Antimony 99.999% 0.125-1 inch chunks |
|||
A34394 | Pfaltz & Bauer | 100G | EUR 224 |
Antimony(III) iodide, 99.999% |
|||
GX5562-10 | Glentham Life Sciences | 10 | EUR 683.6 |
Antimony potassium tartrate trihydrate 99% |
|||
A34540 | Pfaltz & Bauer | 100G | EUR 284.1 |
Antimony(III) fluoride, 99% |
|||
GX8250-250 | Glentham Life Sciences | 250 | EUR 129.6 |
Antimony(III) chloride, 99.99+% |
|||
GX1593-10 | Glentham Life Sciences | 10 | EUR 119.1 |
Antimony(III) chloride, 99.99+% |
|||
GX1593-50 | Glentham Life Sciences | 50 | EUR 407.4 |
Antimony(III) chloride, 99% |
|||
GX2593-250 | Glentham Life Sciences | 250 | EUR 129.6 |
Antimony tetraphenyl bromide_x000D__x000D_ |
|||
A34600 | Pfaltz & Bauer | 5G | EUR 424.28 |
Antimony sulfate 95%_x000D__x000D_ |
|||
A34570 | Pfaltz & Bauer | 5G | EUR 182.3 |
Antimony tin oxide (ATO); 99,95 % |
|||
GX2461-1 | Glentham Life Sciences | 1 | EUR 1311.6 |
Antimony tin oxide (ATO); 99,95 % |
|||
GX2461-100 | Glentham Life Sciences | 100 | EUR 299.9 |
Antimony tin oxide (ATO); 99,95 % |
|||
GX2461-25 | Glentham Life Sciences | 25 | EUR 137.2 |
Antimony tin oxide (ATO); 99,95 % |
|||
GX2461-250 | Glentham Life Sciences | 250 | EUR 496.9 |
Antimony powder 99.995% -200 mesh |
|||
A34389 | Pfaltz & Bauer | 5G | EUR 374.19 |
Antimony Powder -325 mesh, 99.5% |
|||
GX2647-100 | Glentham Life Sciences | 100 | EUR 107 |
Antimony Powder -325 mesh, 99.5% |
|||
GX2647-500 | Glentham Life Sciences | 500 | EUR 259.8 |
Antimony Shot 1-3 mm, 99.9999% |
|||
GX3665-10 | Glentham Life Sciences | 10 | EUR 110 |
Antimony Shot 1-3 mm, 99.9999% |
|||
GX3665-50 | Glentham Life Sciences | 50 | EUR 257.4 |
Antimony Shot 1-3 mm, 99.999% |
|||
GX5423-50 | Glentham Life Sciences | 50 | EUR 208.6 |
Antimony Rod 8 mm diameter, 99.999% |
|||
GX9225-50 | Glentham Life Sciences | 50 | EUR 510 |
Antimony Rod 6 mm diameter, 99.999% |
|||
GX5626-50 | Glentham Life Sciences | 50 | EUR 505.1 |
ICP Std Antimony 1000ug/mL in 1% HCl - 100ML |
|||
PSB2A11 | Scientific Laboratory Supplies | 100ML | EUR 133.66 |
ICP Std Antimony 1000ug/mL in 10% HCl - 100ML |
|||
PSB2A5 | Scientific Laboratory Supplies | 100ML | EUR 135.13 |
ICP Std Antimony 1000ug/mL in 20% HCl - 250ML |
|||
PSB2B5 | Scientific Laboratory Supplies | 250ML | EUR 165.97 |
ICP Std Antimony 1000ug/mL in 10% HCl - 500ML |
|||
PSB2C5 | Scientific Laboratory Supplies | 500ML | EUR 294.3 |
ICP Std Antimony 10000ug/mL in 10% HCl - 100ML |
|||
PSB4A5 | Scientific Laboratory Supplies | 100ML | EUR 233.55 |
ICP Std Antimony 10000ug/mL in 20% HCl - 250ML |
|||
PSB4B5 | Scientific Laboratory Supplies | 250ML | EUR 305.51 |
Antimony Powder max. 250 micron, 99.999% |
|||
GX3000-10 | Glentham Life Sciences | 10 | EUR 125.1 |
Antimony Powder max. 250 micron, 99.999% |
|||
GX3000-100 | Glentham Life Sciences | 100 | EUR 453 |
Antimony Powder max. 250 micron, 99.999% |
|||
GX3000-50 | Glentham Life Sciences | 50 | EUR 272.2 |
ICP Std Antimony 1000ug/mL in 6% Tart. Acid - 250ML |
|||
PSB2B4 | Scientific Laboratory Supplies | 250ML | EUR 171.85 |
×
The proposed technique demonstrates the potential formation of environmentally related U(vi) colloidal nanoparticles showing notably attention-grabbing for the preparation of reference methods within the absence of added ions and capping brokers.
Tags: 3x flag tag dna sequence 3x flag tag sequence corticosterone elisa kit crispr cas9 vector cypridina ecori restriction enzyme geneart crispr gfp plasmid gfp sequence gibson assembly reaction gst protein sequence gst tag sequence invitrogen crispr cas9 kpni lenti 293t lenti blast lenti boost lenti cas9 lenti cells lenti depaul lenti gfp lenti guide lenti latin lenti luca lenti max lenti orf lenti rna lenti shrna lenti srl lenti susi lenti vase lenti vsvg lenti zoo pbsk vector pcdna map pcmv gfp peptide bond peptide yy pet 24 vector pgc 1 alpha antibody pgipz shrna plasmid plasmid mini prep plasmid prep kit protein g agarose ptopo vector map qpcr primers scrambled shrna strep tag sequence taq pol